Teva Pharmaceutical Industries Ltd. has entered a definitive merger agreement to acquire Auspex Pharmaceuticals, Inc. for total consideration of approximately $3.2 billion. The transaction expands Teva’s central nervous system (CNS) franchise.     Auspex’s lead investigational product, SD-809 (deutetrabenazine), leverages its deuterium technology platform, and is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome....